

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM358075

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Wilmington Trust, National Association		09/16/2013	CORPORATION:
RECEIVING PARTY DATA			
Name:	DRUGTECH CORPORATION		
Doing Business As:	Lumara Health IP Ltd.		
Street Address:	16640 Chesterfield Grove Road		
Internal Address:	Suite 200		
City:	Chesterfield		
State/Country:	MISSOURI		
Postal Code:	63005		
Entity Type:	CORPORATION: DELAWARE		
PROPERTY NUMBERS Total: 41			
Property Type	Number	Word Mark	
Registration Number:	2517899	CALCIPURE	
Registration Number:	1156939	CHROMAGEN	
Registration Number:	3395236	CHRONOMETRIC SYSTEM	
Registration Number:	3184560	CLINDESSE	
Registration Number:	2948258	CONTINUUM OF CARE	
Registration Number:	3111521	ENCORA	
Registration Number:	3688522	EVAMIST	
Registration Number:	3550530	EVAMIST	
Registration Number:	1997221	FLAVORTECH	
Registration Number:	1912198	GUAIFENEX	
Registration Number:	2457708	GYNAZOLE 1	
Registration Number:	2031080	HISTA-VENT	
Registration Number:	1932221	HISTINEX	
Registration Number:	4317346	KV PHARMACEUTICAL	
Registration Number:	1293848	METER RELEASE	
Registration Number:	1939204	MICRO RELEASE	
Registration Number:	2031082	NATALCARE	
TRADEMARK			

OP \$1040.00 2517899

Property Type	Number	Word Mark
Registration Number:	804556	NIFEREX
Registration Number:	3291637	NIFEREX GOLD
Registration Number:	2441392	NUTRINATE
Registration Number:	2940425	OMEGANATE
Registration Number:	2719613	PRE CARE CONCEIVE
Registration Number:	1365182	PRECARE
Registration Number:	3320970	PRECARE PREMIER
Registration Number:	2582817	PRIMACARE
Registration Number:	3643470	PRIMACARE ADVANTAGE
Registration Number:	3414475	PRIMACARE ONE
Registration Number:	3406639	REPLIVA
Registration Number:	3389789	REPLIVA 21/7
Registration Number:	1192702	SITE RELEASE
Registration Number:	2742749	STRONGSTART
Registration Number:	4254188	THER-RX
Registration Number:	2948813	THE THER-RX CONTINUUM OF WOMEN'S CARE
Serial Number:	77558671	KV
Serial Number:	77558677	KV PHARMACEUTICAL
Serial Number:	77519812	EVAMIST
Serial Number:	77558690	KV
Serial Number:	77558695	KV PHARMACEUTICAL
Serial Number:	77558703	KV PHARMACEUTICAL
Serial Number:	77466451	LIQUETTE
Serial Number:	77885809	PREMESISRX

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: PeterHart@goodwinprocter.com

Correspondent Name: GOODWIN PROCTER LLP C/O PETER HART

Address Line 1: THE NEW YORK TIMES BUILDING

Address Line 2: 620 EIGHTH AVENUE

Address Line 4: NEW YORK, NEW YORK 10018

NAME OF SUBMITTER: Peter Hart

SIGNATURE: /Peter Hart/

DATE SIGNED: 10/09/2015

Total Attachments: 5

source=25. WTC Trademark Release#page1.tif

source=25. WTC Trademark Release#page2.tif

source=25. WTC Trademark Release#page3.tif

source=25. WTC Trademark Release#page4.tif

source=25. WTC Trademark Release#page5.tif

**RELEASE OF SECURITY INTEREST IN
TRADEMARKS**

THIS RELEASE OF SECURITY INTEREST IN TRADEMARKS (the "Release"), is granted and conveyed as of this 16 day of September, 2013, by Wilmington Trust, National Association (successor by merger to Wilmington Trust FSB), as collateral agent (the "Agent"), in favor of DrugTech Corporation, a Delaware corporation (the "Obligor").

WITNESSETH:

WHEREAS, pursuant to that certain Pledge and Security Agreement, dated as of March 17, 2011, by and among the parties and the other grantors party thereto (the "Security Agreement"), the Obligor granted to the Agent security interests in certain collateral, including the Trademark Collateral (as hereinafter defined);

WHEREAS, in connection with the Security Agreement, the Obligor executed that certain Trademark Security Agreement, dated as of March 17, 2011 (as amended, amended and restated, supplemented or otherwise modified from time to time, the "Trademark Security Agreement"), under which the Obligor mortgaged, pledged and granted to the Agent a lien on, and security interest in and to, all of Obligor's right, title and interest in, to and under the Trademark Collateral (together with the security interests granted pursuant to the Security Agreement, the "Security Interests"), for recording with the United States Patent and Trademark Office and any other appropriate governmental authorities;

WHEREAS, the Trademark Security Agreement was recorded in the United States Patent and Trademark Office on March 18, 2011 at Reel 4501/Frame 0167;

WHEREAS, pursuant to that certain Order Confirming Sixth Amended Joint Chapter 11 Plan of Reorganization for K-V Discovery Solutions, Inc. and its Affiliated Debtors (the "Order"), entered in the United States Bankruptcy Court, Southern District of New York on August 29, 2013 in connection with the Sixth Amended Joint Chapter 11 Plan of Reorganization of K-V Discovery Solutions and its Affiliated Debtors, dated July 17, 2013 (the "Plan"), the Obligor and Agent are authorized, upon the Effective Date (as defined in the Plan), to: (a) terminate and release all liens and interests of the Agent in the Trademark Collateral and (b) execute and deliver evidence of such termination and release for filing in the United States Patent and Trademark Office;

WHEREAS, all conditions to the occurrence of the Effective Date (as defined in the Plan) have occurred and the Effective Date (as defined in the Plan) is the same as the date of this Release; and

WHEREAS, all conditions to the release of the Agent's Security Interests in the Trademark Collateral have been satisfied, and the parties seek to make record of the Agent's release to the Obligor of any and all of its Security Interests in the Trademark Collateral.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Definitions. All capitalized terms used herein and not otherwise defined shall have the meanings ascribed thereto in the Security Agreement. The term “Trademark Collateral,” as used herein, shall mean (a) all of the Obligor’s right, title and interest in and to the trademarks, trademark registrations, and trademark applications listed on Schedule A hereto, and all of the goodwill of the business connected with the use of, and symbolized by, each such trademark, trademark registration and trademark application; (b) all renewals of the foregoing; and (c) all proceeds of the foregoing, including without limitation any claim against third parties for damages by reason of past, present or future infringement or dilution of any trademark, trademark registration, or trademark application listed on Schedule A hereto or by reason of injury to the goodwill associated with any such trademark, trademark registration, or trademark application, in each case together with the right to sue for and collect said damages.

2. Release of Security Interests. The Agent hereby terminates, discharges and releases to the Obligor the Security Interests in the Trademark Collateral, and any right, title or interest of the Agent in such Trademark Collateral shall hereby cease and become void.


3. Further Assurances. The Agent hereby agrees to duly execute, acknowledge, procure and deliver, at the sole expense of the Obligor or its successors and assigns, any further documents and to do such other acts as may be reasonably necessary to effect the termination, release, discharge or reassignment to the Obligor of the Security Interests contemplated hereby.

4. Governing Law. This Release shall be governed by, and construed in accordance with, the laws of the State of New York.

[signature page follows]

IN WITNESS WHEREOF, the Agent has caused this Release to be duly executed and delivered by its officer thereunto duly authorized as of the date first above written.

WILMINGTON TRUST, NATIONAL
ASSOCIATION (successor by merger to
Wilmington Trust FSB), as Agent

By: 
Name: Peter Pinkert
Title: V.P.

[Signature Page to Release of Security Interest in Trademarks]

SCHEDULE A**TRADEMARKS**

Trademark	Registration No.	Registration Date	Owner
CALCIPURE	2,517,899	12/11/2001	Drugtech Corporation
CHROMAGEN	1,156,939	6/9/1981	
CHRONOMETRIC SYSTEM	3,395,236	3/11/2008	Drugtech Corporation
CLINDESSE	3,184,560	12/12/2006	Drugtech Corporation
CONTINUUM OF CARE	2,948,258	5/10/2005	Drugtech Corporation
ENCORA	3,111,521	7/4/2006	Drugtech Corporation
EVAMIST and Design	3,688,522	9/29/2009	Drugtech Corporation
EVAMIST	3,550,530	12/23/2008	Drugtech Corporation
FLAVORTECH (Stylized)	1,997,221	8/27/1996	Drugtech Corporation
GUAIFENEX	1,912,198	8/15/1995	Drugtech Corporation
GYNAZOLE 1	2,457,708	6/5/2001	Drugtech Corporation
HISTA-VENT	2,031,080	1/14/1997	Drugtech Corporation
HISTINEX	1,932,221	10/31/1995	Drugtech Corporation
KV PHARMACEUTICAL and Design	4,317,346	4/9/2013	Drugtech Corporation
METER RELEASE	1,293,848	9/11/1984	Drugtech Corporation
MICRO RELEASE	1,939,204	12/5/1995	Drugtech Corporation
NATALCARE	2,031,082	1/14/1997	Drugtech Corporation
NIFEREX (Stylized)	804,556	3/1/1966	Drugtech Corporation
NIFEREX GOLD	3,291,637	9/11/2007	Drugtech Corporation
NUTRINATE	2,441,392	4/3/2001	Drugtech Corporation

OMEGANATE	2,940,425	4/12/2005	Drugtech Corporation
PRE CARE CONCEIVE	2,719,613	5/27/2003	Drugtech Corporation
PRECARE	1,365,182	10/15/1985	Drugtech Corporation
PRECARE PREMIER	3,320,970	10/23/2007	Drugtech Corporation
PRIMACARE	2,582,817	6/18/2002	Drugtech Corporation
PRIMACARE ADVANTAGE	3,643,470	6/23/2009	Drugtech Corporation
PRIMACARE ONE	3,414,475	4/22/2008	Drugtech Corporation
REPLIVA	3,406,639	4/1/2008	Drugtech Corporation
REPLIVA 21/7	3,389,789	2/26/2008	Drugtech Corporation
SITE RELEASE	1,192,702	3/30/1982	Drugtech Corporation
STRONGSTART	2,742,749	7/29/2003	Drugtech Corporation
THER-RX	4,254,188	12/4/2012	Drugtech Corporation
THE THE-RX CONTINUUM OF WOMEN'S CARE and Design	2,948,813	5/10/2005	Drugtech Corporation

U.S. Trademark Applications

Trademark	Application No.	Application Date	Owner
KV	77/558,671	8/29/2008	Drugtech Corporation
KV PHARMACEUTICAL	77/558,677	8/29/2008	Drugtech Corporation
EVAMIST	77/519,812	7/10/2008	Drugtech Corporation
KV	77/558,690	8/29/2008	Drugtech Corporation
KV PHARMACEUTICAL	77/558,695	8/29/2008	Drugtech Corporation
KV PHARMACEUTICAL	77/558,703	8/29/2008	Drugtech Corporation
LIQUETTE	77/466,451	5/6/2008	Drugtech Corporation
PREMESISRX	77/885,809	12/3/2009	Drugtech Corporation